Roivant Sciences secures $5.2B for advancing late-stage drugs like IMVT-1402 & brepocitinib. Click here to read an analysis ...

Autoimmune diseases specialist Immunovant has announced changes to its leadership team and the expanded development of its ...

Fintel reports that on April 22, 2025, UBS downgraded their outlook for Immunovant (NasdaqGS:IMVT) from Buy to Neutral.

UBS downgraded Immunovant (IMVT) to Neutral from Buy with a price target of $17, down from $38.Stay Ahead of the Market: Discover ...

Immunovant, Inc. (NASDAQ: IMVT) has announced a significant shift in its leadership team and the expansion of its drug ...

That means the future of Roivant is tied to the success, or otherwise, of Immunovant’s attempts to break into the FcRn market ...

Immunovant, Inc. (IMVT) announced on Monday that Roivant President Eric Venker will succeed Pete Salzmann as the new CEO, ...

Immunovant (IMVT) announced next phase of growth including changes to its leadership team and the expanded development of IMVT-1402 into two ...

$IMVT insiders have traded $IMVT stock on the open market 30 times in the past 6 months. Of those trades, 1 have been purchases and 29 have been sales.